Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464917 | 0.86 | CHRM5 (0.75) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL25083196 | 0.86 | SMN1; SMN2 (0.56) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16228134 | 0.84 | SMN1; SMN2 (0.54) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16118687 | 0.84 | SMN1; SMN2 (0.54) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18743787 | 0.84 | CHRM5 (0.72) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7721235 | 0.84 | CHRM5 (0.72) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL26042973 | 0.83 | KDM4E (0.53) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL26451646 | 0.83 | KDM4E (0.53) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13417680 | 0.82 | CHRM5 (0.70) | CHRM5CHRM3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13396798 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1PKMHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3655401-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| WO-2018099952-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2018-06-07 | — | — | WO | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2017005137-A1 | QUINAZOLINE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | 吉林大学 | 2017-01-12 | — | — | WO | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-7300948-B2 | Alkynyl compounds as non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | CHRM5 3554/4885CHRM3 2978/4885SMN1; SMN2 686/4885 |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | CHRM5 4867/4885CHRM3 4818/4885SMN1; SMN2 4806/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | CHRM5 1387/4885CHRM3 1606/4885SMN1; SMN2 4476/4885 |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CHRM5 1920/4885CHRM3 1535/4885SMN1; SMN2 2066/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | CHRM5 1387/4885CHRM3 1606/4885SMN1; SMN2 4476/4885 |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | CHRM5 2087/4885CHRM3 1614/4885SMN1; SMN2 1984/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | CHRM5 1387/4885CHRM3 1606/4885SMN1; SMN2 4476/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | CHRM5 4833/4885CHRM3 4544/4885SMN1; SMN2 3927/4885 |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CHRM5 1492/4885CHRM3 1334/4885SMN1; SMN2 2610/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CHRM5 1492/4885CHRM3 1334/4885SMN1; SMN2 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.